StocksRunner logo
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  Highlights  
 
  Updates  
 
 
 
Bristol-Myers Squibb
50.89
+0.32%
 

BMY

 

Bristol-Myers Squibb

$ 50.89

 
+$0.16 | +0.32%
 
 
Open
$ 50.94
 
 
MKT CAP
$ 102.91B
 
High
$ 51.08
 
 
VOL
$ 10.71M
 
Low
$ 50.44
 
 
AVG VOL
$ 14.77M
 
 
 

BMY Stock Analysis

  Login to display Bristol-Myers Squibb (BMY) recommendation from the last 90 days from financial news and social media.
 
 

BMY Total Score

 
 

Strengths

BMY Rewards

 Insider buying over the past 3 months

BMY Rewards

 Earnings are forecast to grow

BMY Rewards

 Investors confidence is positive

BMY Rewards

 Trading below its fair value

 

Risk Analysis

BMY Risk Analysis

 Downgraded on weak valued

 
 

Chart

 
 

50.11

50.1

56.48

67.29

 
 
1month
3month
6month
1year
 

BMY Risk Level

This Indicator assigning BMY risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
BMY Risk Level
LOW
HIGH

Risk Volatility

 

BMY has Low Risk Level

Click here to check what is your level of risk

 

BMY Analysts Opinion

BMY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

3.87
 

BMY Earnings Sentiment

 Reported a strong earnings

BMY Earnings Sentiment

 Above analyst estimates

BMY Earnings Sentiment

 Sales increase

BMY Earnings Sentiment

 Earnings decline YoY

 
 

Rating

×
 

Rating

2.25
 

BMY Rating Sentiment

 Downgraded on weak valued

 

Momentum

×
 

Momentum

3.40
 

BMY Momentum Analysis

 Has been gaining momentum

 

Activity

×
 

Activity

3.88
 

BMY Activity Sentiment

 Insider buying over the past 3 months

BMY Activity Sentiment

 Investors confidence is positive

BMY Activity Sentiment

 Pays a reliable dividend

 

Future

×
 

Future

3.71
 

BMY Future Sentiment

 Earnings are forecast to grow

BMY Future Sentiment

 Trading below its fair value

BMY Future Sentiment

 Outperform the market

 
 

BMY Analysts Opinion

BMY Analysts opinion is negative and has getting worse from the past 3 months

 

BMY Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
81%
Buy
Opinion
Trend
Score
Potential
Score
 
 
0%
60%
86%
 
On Track
On Track
On Track
 

BMY Street Opinion 

BMY Street view is extremely ish and have positive views on the near-term outlook

 

BMY Performance Sentiment

Sentiments overview associated with BMY events and the stock performance.
 
81%
10%
Positive
Negative
51 out of 63
events present
6 out of 63
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

BMY Earnings

The TTM reflects 12-month period, providing review of BMY financial performance.

 
Millions of Dollars
TTM
2023
2022
CAGR
 

 
Total Revenue
45,006
45,006
46,159
-1.26%
 
 
Cost of Revenue
10,693
10,693
10,137
+2.71%
 
 
Gross Profit
34,313
34,313
36,022
-2.40%
 
 
Operating Exp
26,118
26,118
26,918
-1.50%
 
 
Operating Inc
8,195
8,195
9,104
-5.12%
 
 
Net Interest Inc
-1,166
-1,166
-1,232
-
 
 
Interest Exp
1,166
1,166
1,232
-2.72%
 
 
Other Income
1,411
1,411
-159
-
 
 
EPS
3.97
-
2.97
+15.62%
 
 
Next Earnings Date: Apr 25, 2024
 
 
Similar to BMY
Total Score
Close Price
%
Change

PFE

Pfizer

3.47

26.59

+0.11%

 

NVS

Novartis AG

3.59

102.06

+1.11%

 

EVO

Evotec SE American

N/A

7.53

+1.76%

 

ABBV

AbbVie

3.32

178.91

+1.62%

 

GILD

Gilead Sciences

2.87

72.31

+0.29%

 
 
 
Highlights
Last Modify
Price
% Change

 
Dividend Declares
This Week
50.89
+0.32%
 
Investors Buying
This Week
50.75
-0.33%
 
Insider Buying
This Week
50.51
-0.02%
 
HR Activity
1 Week Ago
49.86
0.00%
 
Insider Buying
2 Weeks Ago
49.44
+1.12%
 
 
 
joker
 
 
 
StocksRunner

Explore our BMY Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored FDX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our BMY Daily Alerts

Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo

StocksRunner

Get the pulse of the market

 
StocksRunner
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 

BMY Rewards

 Insider buying over the past 3 months

BMY Rewards

 Earnings are forecast to grow

BMY Rewards

 Investors confidence is positive

BMY Rewards

 Trading below its fair value

 

Risk Analysis

 

BMY Risk Analysis

 Downgraded on weak valued

 
 
 

BMY Risk Level

 
 
 

The Indicator assigning BMY risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
 
BMY Risk Level
LOW
HIGH

Risk Volatility

 

BMY has Low Risk Level. Click here to check what is your level of risk

 
 
 
 

Stock Analysis

 
 
 
 

BMY

 

Bristol-Myers Squibb

$ 50.89

 
+$0.16 | +0.32%
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 

 
joker
 
 
 
Open
$ 50.94
 
 
MKT CAP
$ 102.91B
 
High
$ 51.08
 
 
VOL
$ 10.71M
 
Low
$ 50.44
 
 
AVG VOL
$ 14.77M
 
 
 

BMY Analysis

  Sign in to view Bristol-Myers Squibb (BMY) recommendation from the last 90 days from financial news and social media.
 
 

Chart

 
 

50.11

50.1

56.48

67.29

 
 
1month
3month
6month
1year
 

BMY Analysts Opinion

BMY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

3.87
 

BMY Earnings Sentiment

 Reported a strong earnings

BMY Earnings Sentiment

 Above analyst estimates

BMY Earnings Sentiment

 Sales increase

BMY Earnings Sentiment

 Earnings decline YoY

 
 

Rating

×
 

Rating

2.25
 

BMY Rating Sentiment

 Downgraded on weak valued

 

Momentum

×
 

Momentum

3.40
 

BMY Momentum Sentiment

 Has been gaining momentum

 

Activity

×
 

Activity

3.88
 

BMY Activity Sentiment

 Insider buying over the past 3 months

BMY Activity Sentiment

 Investors confidence is positive

BMY Activity Sentiment

 Pays a reliable dividend

 

Future

×
 

Future

3.71
 

BMY Future Sentiment

 Earnings are forecast to grow

BMY Future Sentiment

 Trading below its fair value

BMY Future Sentiment

 Outperform the market

 
 

BMY Analysts Opinion

BMY Analysts opinion is negative and has getting worse from the past 3 months

 

BMY Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
81%
Buy
Opinion
Trend
Score
Potential
Score
 
 
0%
60%
86%
 
On Track
On Track
On Track
 

BMY Street Opinion 

BMY Street view is extremely ish and have positive views on the near-term outlook

 
BMY Performance Sentiment
Sentiments overview associated with BMY events and the stock performance.
 
81%
10%
Positive
Negative
51 out of 63
events present
6 out of 63
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

BMY Earnings

The TTM data reflects the most recent 12-month period, providing overview of BMY financial performance.

 
Millions of Dollars
TTM
2023
2022
CAGR
 

 
Total Revenue
45,006
45,006
46,159
-1.26%
 
 
Cost of Revenue
10,693
10,693
10,137
+2.71%
 
 
Gross Profit
34,313
34,313
36,022
-2.40%
 
 
Operating Exp
26,118
26,118
26,918
-1.50%
 
 
Operating Inc
8,195
8,195
9,104
-5.12%
 
 
Net Interest Inc
-1,166
-1,166
-1,232
-
 
 
Interest Exp
1,166
1,166
1,232
-2.72%
 
 
Other Income
1,411
1,411
-159
-
 
 
EPS
3.97
-
2.97
+15.62%
 
 
Next Earnings Date: Apr 25, 2024
 
Highlights
Last Modify
Price
% Change

 
Dividend Declares
This Week
50.89
+0.32%
 
Investors Buying
This Week
50.75
-0.33%
 
Insider Buying
This Week
50.51
-0.02%
 
HR Activity
1 Week Ago
49.86
0.00%
 
Insider Buying
2 Weeks Ago
49.44
+1.12%
 
 
BMY Latest News Feed

Bristol Myers Squibb (BMY) Rises But Trails Market: What Investors Should Know. In the latest trading session Bristol Myers Squibb (BMY) closed at $50.89 marking a 0.28% move from the previous day. This change lagged the S&.P 500s 0.8% gain on the day. Elsewhere the Dow gained 0.23% while the tech-he

Fri Mar 1, 2024

Momentum

Bristol-Myers Squibb Company  declares $0.60 dividend.

Fri Mar 1, 2024

Activity

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It. Bristol Myers Squibb (BMY) has recently been on Zacks.coms list of the most searched stocks. Therefor

Thu Feb 29, 2024

Activity

Bristol Myers Squibb Named Top Dividend Stock With Insider Buying and 4.75% Yield (BMY). In this series we look through the most recent Dividend Channel DividendRank report and then we cherry pick only those companies that have experienced insid

Tue Feb 27, 2024

Activity
Potential

Bristol Myers CEO says India to have largest R&D presence outside US by 2025. Bristol Myers Squibb aims to expand its research and development presence in India and expects its newly inaugurated Hyderabad facility to become its largest unit outs

Tue Feb 27, 2024

Activity

Bristol Myers blood disorder therapy endorsed in EU for label expansion.

Fri Feb 23, 2024

Activity

BMS to create 350 jobs in $400m Cruiserath expansion. The new investment will significantly expand the pharma companys manufacturing and laboratory capacity at the Dublin 15 campus. Pharma giant Bristol Myers Squibb (BMS) has announced a $400m investment

Fri Feb 23, 2024

Activity

Aurora Cannabis names former Bristol Myers executive as CFO. Canadian pot firm Aurora Cannabis said on Tuesday it has appointed Simona King a former executive of Bristol Myers-Squibb as its Chief Financial Officer.

Tue Feb 20, 2024

Activity

Insiders Buy the Holdings of DIVB ETF. A look at the weighted underlying holdings of the iShares Core Dividend ETF (DIVB) shows an impressive 12.6% of holdings on a weighted basis have experienced insider buying within the past six months.

Thu Feb 15, 2024

Activity
Potential

Bristol Myers wins FDA review for label expansion of lung cancer therapy.

Wed Feb 14, 2024

Activity

Bristol Myers Squibb RayzeBio Report Expiration Of HSR Act Waiting Period. (RTTNews) - Bristol Myers Squibb (BMY) and RayzeBio Inc. (RYZB) announced the expiration of the waiting period under the HSR Act Waiting Period in connection with Bristol

Mon Feb 12, 2024

Activity
Potential

bristol myers (bmy) opdivo label expansion filings get accepted. bristol myersbmy announced the acceptance of its regulatory applications for neoadjuvant opdivo (nivolumab) with chemotherapy fo

Thu Feb 8, 2024

Activity

bristol myers granted fda eu reviews for opdivo label expansion.

Wed Feb 7, 2024

Activity

bristol myers cut at redburn as looming headwinds offset buyouts.

Tue Feb 6, 2024

Potential
Rating

bristol myers squibb shares cross 5% yield mark. in trading on monday shares of bristol myers squibb were yielding above the 5% mark based on its quarterly dividend (annualized to $2.4) with the stock changing hands as low as $47.68 on the day. dividends

Mon Feb 5, 2024

Activity

bristol-myers squibb beats top-line and bottom-line estimates. initiates fy24 outlook.

Fri Feb 2, 2024

Earnings

bristol-myers squibb beats in q4 as eliquis and opdivo outperform.

Fri Feb 2, 2024

Potential

bristol myers squibb results top estimates as new drugs post strong sales growth . bristol myers squibb also issued its full-year 2024 forecast which was generally in line with expectations.

Fri Feb 2, 2024

Earnings

bristol myers squibb results top expectations as newer drugs help fuel growth. bristol myers squibb co. bmy on friday reported fourth-quarter results that beat analysts expectations helped by portfolio stalwarts like the blood thinner eliquis as well as s

Fri Feb 2, 2024

Earnings
Potential

bristol myers shares rise on fourth-quarter earnings beat. bristol myers earnings came in above expectations although opdivo sales were slower than expected. bmy stock gained. the post bristol myers shares rise on fourth-quarter earnings beat appeared fir

Fri Feb 2, 2024

Earnings
Momentum

earnings preview: bristol myers seen reporting lower q4 earnings friday.

Thu Feb 1, 2024

Earnings

insiders now seeing red with bmy at new 52-week low. in trading on thursday shares of bristol myers squibb co. (symbol: bmy) touched a new 52-week low of $48.12/share. thats a $27.06 share price drop or -35.99% decline from the 52-week high

Thu Feb 1, 2024

Momentum

guru fundamental report for bmy. below is valideas guru fundamental report for bristol-myers squibb co (bmy). of the 22 guru strategies we follow bmy rates highest using our low pe investor model based on the published strategy of john neff. th

Thu Feb 1, 2024

Earnings

bristol myers (bmy) sblas for breyanzi get fda priority tag. bristol myers squibb company bmy announced that the fda has accepted its two supplemental biologics license applications (sbla) seek

Wed Jan 31, 2024

Activity

bmy quantitative stock analysis. below is valideas guru fundamental report for bristol-myers squibb co (bmy). of the 22 guru strategies we follow bmy rates highest using our low pe investor model based on the published strategy of john neff. th

Tue Jan 30, 2024

Earnings

bristol-myers says regulatory applications for breyanzi accepted by fda japans mhlw. (rttnews) - bristol-myers squibb co. (bmy) announced tuesday that the fda has accepted two supplemental biologics license applications or sbla for breyanzi for

Tue Jan 30, 2024

Activity

bristol myers sees $0.35 per share impact as mirati acquisition completes.

Tue Jan 23, 2024

Activity

bristol-myers almost lost karuna buyout to third party.

Mon Jan 22, 2024

Activity

validea detailed fundamental analysis - bmy. below is valideas guru fundamental report for bristol-myers squibb co (bmy). of the 22 guru strategies we follow bmy rates highest using our low pe investor model based on the published strategy of j

Mon Jan 22, 2024

Earnings

mirati therapeutics ticks higher amid nasdaq delisting for sale to bristol-myers.

Fri Jan 19, 2024

Activity

 
 
 
 
 

Score Tracker

 
 
 
Based on 63 events in the last 90 days from financial news and social media. Last updated Mar 1, 2024 23:12 Wall St. time
 
 

BMY Total Score

 
 
 
 
 
 
 
StocksRunner

Discover BMY Stock analysis and effective trading strategies with StocksRunner. Gain valuable insights into stock performance, market trends, and the future potential of BMY. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our BMY Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

BMY Stock trends

BMY Stock performance

BMY Stock analysis

BMY investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
Post ×
 
0/666
joker